Author Correction: Antisense oligonucleotide development for the selective modulation of CYP3A5 in renal disease
Sci Rep
.
2021 May 17;11(1):10711.
doi: 10.1038/s41598-021-90075-z.
Authors
Kevin A Lidberg
#
1
,
Andrew J Annalora
#
2
,
Marija Jozic
3
,
Daniel J Elson
3
,
Lu Wang
4
,
Theo K Bammler
4
,
Susanne Ramm
5
,
Maria Beatriz Monteiro
6
,
Jonathan Himmelfarb
7
,
Craig B Marcus
3
,
Patrick L Iversen
3
,
Edward J Kelly
8
Affiliations
1
Department of Pharmaceutics, University of Washington, Seattle, WA, USA.
2
Department of Environmental and Molecular Toxicology, Oregon State University, Corvallis, OR, USA. Andrew.Annalora@oregonstate.edu.
3
Department of Environmental and Molecular Toxicology, Oregon State University, Corvallis, OR, USA.
4
Department of Environmental and Occupational Health Sciences, University of Washington, Seattle, WA, USA.
5
Victorian Centre for Functional Genomics, Peter MacCallum Cancer Centre, Melbourne, Australia.
6
Depto Clinica Medica, Faculdade de Medicina FMUSP, Universidade de Sao Paulo, São Paulo, Brazil.
7
Kidney Research Institute, University of Washington, Seattle, WA, USA.
8
Department of Pharmaceutics, University of Washington, Seattle, WA, USA. Edkelly@uw.edu.
#
Contributed equally.
PMID:
34002000
PMCID:
PMC8128877
DOI:
10.1038/s41598-021-90075-z
No abstract available
Publication types
Published Erratum
Grants and funding
P30 ES007033/ES/NIEHS NIH HHS/United States